UNASSIGNED: High affinity @entity1501 receptor (HFR) can be overexpressed in @entity0 and is associated with poor prognosis, however the expression in @entity0 ( @entity0 ) is unknown. The aim of this study was to analyze the rate of HFR expression in @entity0 and its role in the prognosis of this high-risk cohort. We analyzed 19 brain @entity3 (BM) and 13 @entity5 ( @entity5 ) from a total of 25 @entity1 . HFR status was assessed by immunohistochemistry. Median follow-up was 4.2 years (range 0.6-18.5). HFR was positive in 4/19 BM (21.1%) and in 1/13 @entity5 (7.7%). Positive samples had low H-scores (range 1-50). 56% of @entity1 had apocrine differentiation. @entity3012 was similar between @entity1 with positive HFR (median @entity3012 48 months) and negative HFR (median @entity3012 69 months) (P = 0.25); and between @entity1 with apocrine differentiation (median @entity3012 63 months) and those without apocrine differentiation (median @entity3012 69 months) (P = 0.49). To the best of our knowledge, this is the first analysis of HFR expression in @entity0 . While previous studies associated the presence of HFR with worse prognosis; in our cohort HFR was positive in only 21.1% of BM with low levels of positivity. Neither HFR nor apocrine features had impact in @entity3012 .

Expression of high affinity @entity1501 receptor in @entity0 brain XXXX .

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folate'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer brain metastases', 'BCBM', 'breast cancer'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumors', 'PT'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity3 :: (MESH:D009362,Disease) :: ['metastasis']
